Published in Int J Dermatol on September 01, 2001
Scabies. BMJ Clin Evid (2008) 0.75
Comment on "Is a single dose of ivermectin sufficient in crusted scabies?". Int J Dermatol (2002) 0.75
Scabies. BMJ Clin Evid (2014) 0.75
Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res (1996) 2.86
Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206. Mol Biol Cell (1998) 2.24
Neonatal neutropenia in low birthweight premature infants. Am J Perinatol (1995) 1.74
C3a and C5a stimulate chemotaxis of human mast cells. Blood (1997) 1.55
EAACI/GA2LEN/EDF guideline: definition, classification and diagnosis of urticaria. Allergy (2006) 1.55
Fastest reduction of posttraumatic edema: continuous cryotherapy or intermittent impulse compression? Foot Ankle Int (1997) 1.52
Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol (1999) 1.40
[Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy]. Hautarzt (1993) 1.39
Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol (1994) 1.39
Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am (2006) 1.38
[Urticaria pigmentosa and mastocytosis]. Dtsch Med Wochenschr (1998) 1.38
The beta-tubulin gene family of Arabidopsis thaliana: preferential accumulation of the beta 1 transcript in roots. Gene (1988) 1.31
EAACI/GA2LEN/EDF guideline: management of urticaria. Allergy (2006) 1.28
Primary carcinoma of ectopic axillary breast tissue. J Eur Acad Dermatol Venereol (2006) 1.26
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol (1997) 1.16
Mast cells and their mediators in cutaneous wound healing--active participants or innocent bystanders? Exp Dermatol (1999) 1.13
Acute urticaria: clinical aspects and therapeutic responsiveness. Acta Derm Venereol (1996) 1.10
Stabilization of proximal tibial fractures with the LIS-System: early clinical experience in Berlin. Injury (2003) 1.10
Metastatic potential of human melanoma cells in nude mice--characterisation of phenotype, cytokine secretion and tumour-associated antigens. Br J Cancer (1996) 1.09
Miliaria crystallina in an intensive care setting. Clin Exp Dermatol (2004) 1.08
Screening methods using sulfamethazine for determining acetylator phenotype. Clin Pharmacol Ther (1979) 1.06
Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol (1998) 1.06
The beta-tubulin gene family in Zea mays: two differentially expressed beta-tubulin genes. Plant Mol Biol (1990) 1.04
Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol (1995) 1.04
Keratin 17 gene expression during the murine hair cycle. J Invest Dermatol (1997) 1.03
Treatment of femoral shaft fractures in children by external fixation. Injury (1991) 1.02
Topical calcitriol enhances normal hair regrowth but does not prevent chemotherapy-induced alopecia in mice. Cancer Res (1996) 1.02
Phenotypic evaluation of cultured human mast and basophilic cells and of normal human skin mast cells. Arch Dermatol Res (1994) 1.02
Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol (1999) 1.01
Psychiatric comorbidity: prevalence in methadone maintenance treatment. Am J Drug Alcohol Abuse (1996) 0.99
Magnetic resonance imaging in the diagnosis of acute injured distal tibiofibular syndesmosis. Invest Radiol (1997) 0.99
Mast cells and vasculature in atopic dermatitis--potential stimulus of neoangiogenesis. Allergy (2005) 0.97
Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol (2000) 0.97
Demonstration of the high-affinity IgE receptor on human Langerhans cells in normal and diseased skin. Br J Dermatol (1993) 0.97
Impact of vaccinations and infectious diseases on the risk of melanoma--evaluation of an EORTC case-control study. Eur J Cancer (2003) 0.97
Patterns of cell death: the significance of apoptosis for dermatology. Exp Dermatol (1993) 0.96
Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J Immunol (1998) 0.96
Molecular regulation of human IgE synthesis. J Mol Med (Berl) (1997) 0.95
[Vertebroplasty and kyphoplasty in osteoporotic fractures of vertebral bodies -- a prospective 1-year follow-up analysis]. Rofo (2005) 0.95
Pinless external fixation. Indications and preliminary results in tibial shaft fractures. Clin Orthop Relat Res (1998) 0.94
Human skin mast cells rapidly release preformed and newly generated TNF-alpha and IL-8 following stimulation with anti-IgE and other secretagogues. Exp Dermatol (2001) 0.94
Differential expression of angiotensin receptors in human cutaneous wound healing. Br J Dermatol (2005) 0.94
Mastocytosis: recent advances in defining the disease. Br J Dermatol (2001) 0.94
Ultrastructural detection of Haemophilus ducreyi in biopsies of chancroid. Arch Dermatol Res (1978) 0.94
Quantitative detection of soluble adhesion molecules in sera of melanoma patients correlates with clinical stage. Dermatology (1996) 0.93
Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer. Melanoma Res (1999) 0.93
Release of stem cell factor from a human keratinocyte line, HaCaT, is increased in differentiating versus proliferating cells. J Invest Dermatol (1996) 0.92
Novel unconventional therapeutic approaches to atopic eczema. Dermatology (2000) 0.91
Antitumour activity of paclitaxel and interferon-alpha in a case of metastatic eccrine porocarcinoma. J Eur Acad Dermatol Venereol (2004) 0.91
Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol (1999) 0.91
Production of interleukin-6 by human mast cells and basophilic cells. J Invest Dermatol (1996) 0.91
Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia (1994) 0.91
Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients. Eur J Cancer (2005) 0.91
Identification of the bacteriophage T4 unf ( = alc) gene product, a protein involved in the shutoff of host transcription. Genetics (1984) 0.90
Microscopic morphology of different types of urticaria. Arch Dermatol (1998) 0.90
Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study. Br J Cancer (1998) 0.90
Retinoic acid inhibits CD40 + interleukin-4-mediated IgE production in vitro. Blood (1998) 0.90
[Distal radius fracture. Fracture stabilization with biodegradable osteosynthesis pins (Biofix). Experimental studies and initial clinical experiences]. Unfallchirurg (1989) 0.90
Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone. Br J Dermatol (2000) 0.90
Clinical experience with two types of pelvic C-clamps for unstable pelvic ring injuries. Injury (1996) 0.89
Foreign-body granuloma and IgE-pseudolymphoma after multiple bee stings. Br J Dermatol (1994) 0.89
Definition, classification, and routine diagnosis of urticaria: a consensus report. J Investig Dermatol Symp Proc (2001) 0.89
Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol (1996) 0.89
Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (1996) 0.89
Comparative cytokine gene expression: regulation and release by human mast cells. Immunology (1998) 0.89
The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol (2001) 0.88
Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia. Blood (2000) 0.88
Detection of human papillomaviruses in paraffin-embedded condylomata acuminata--comparison of immunohistochemistry, in situ hybridization, and polymerase chain reaction. J Invest Dermatol (1991) 0.88
Laser-induced weal and flare reactions: clinical aspects and pharmacological modulation. Br J Dermatol (2002) 0.87
Human leukaemic (HMC-1) and normal skin mast cells express beta 2-integrins: characterization of beta 2-integrins and ICAM-1 on HMC-1 cells. Scand J Immunol (1997) 0.87
Detection of intracellular interleukin-8 in human mast cells: flow cytometry as a guide for immunoelectron microscopy. J Histochem Cytochem (1997) 0.87
Hair growth control by immunosuppression. Arch Dermatol Res (1996) 0.87
Angiotensin-converting enzyme inhibitors as inducers of adverse cutaneous reactions. Acta Derm Venereol (2002) 0.87
The transcription factor profile of human mast cells in comparison with monocytes and granulocytes. Cell Mol Life Sci (2005) 0.87
Mast cell chymase and tryptase during tissue turnover: analysis on in vitro mitogenesis of fibroblasts and keratinocytes and alterations in cutaneous scars. Exp Dermatol (1999) 0.86
Hair cycle-dependent changes in the gene expression and protein content of transforming factor beta 1 and beta 3 in murine skin. Arch Dermatol Res (1997) 0.86
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol (1996) 0.86
Primary leiomyosarcoma of the skin. A histological and immunohistochemical analysis. Acta Derm Venereol (1993) 0.86
[Osteosynthesis of distal radius fractures with biodegradable fracture rods. Results of two years follow-up]. Unfallchirurg (1992) 0.86
Homologous growth hormone accelerates bone healing--a biomechanical and histological study. Bone (2003) 0.86
Interleukin-6 expression in the skin of patients with lupus erythematosus. Exp Dermatol (1995) 0.86
[Percutaneous reduction and stabilization of a dislocated acetabular fracture. Case report]. Unfallchirurg (2006) 0.86
Crossreacting IgG antibodies against fox mite antigens in human scabies. Arch Dermatol Res (2004) 0.85
[Ipsilateral fractures of the proximal femur and the femoral shaft (author's transl)]. Unfallheilkunde (1980) 0.85
Expression of stem cell factor in cutaneous mastocytosis. Br J Dermatol (1995) 0.85
[Periprosthetic infection]. Chirurg (2011) 0.85
Mastocytosis: review of clinical and experimental aspects. J Investig Dermatol Symp Proc (2001) 0.85
[Classification and management of complex pelvic trauma]. Unfallchirurg (1992) 0.85
Medium dose isotretinoin for the treatment of acne. J Eur Acad Dermatol Venereol (1998) 0.84
[Results of different surgical procedures in the treatment of fresh injuries of the thoracic and lumbar spine]. Unfallchirurg (1987) 0.84
Changes in plasma epinephrine concentration after dental infiltration anesthesia with different doses of epinephrine. J Dent Res (1989) 0.84
GM-CSF downmodulates c-kit, Fc(epsilon)RI(alpha) and GM-CSF receptor expression as well as histamine and tryptase levels in cultured human mast cells. Arch Dermatol Res (2001) 0.84
Muckle-Wells syndrome: clinical and histological skin findings compatible with cold air urticaria in a large kindred. Br J Dermatol (2004) 0.84
Interactions of immature human mast cells with extracellular matrix: expression of specific adhesion receptors and their role in cell binding to matrix proteins. J Invest Dermatol (1996) 0.83